The Translational Pharmacology and Early Therapeutic Trials Program (formerly Experimental Therapeutics Program) focuses on development of new cancer therapies. It conducts Phase I & II trials in partnership with industry, NCI and it’s own DF/HCC investigators. This Program provides toxicity information and pharmacokinetics for new agents, enabling implementation of Phase II clinical trials. Another Program goal is training clinical investigators in the science and regulatory aspects of drug development.
This Program is an essential conduit for preclinical and clinical development of agents identified in other DF/HCC Programs, the NCI, and biotechnology/pharmaceutical companies. It has expanded by integrating its clinical trials activities with those of basic scientists in the discipline-based programs and clinical investigators in the disease-based programs; this collaboration has broadened the scope of the Program by providing expertise, advice, and collaboration in translational research to academic partners who wish to bring new agents into the clinical setting.
The scientific goals of the Program are: